Medication
Mint-Irbesartan
DIN 02423006 · Mint Pharmaceuticals Inc Likely a generic
What it is
- Active ingredients
- Irbesartan — 300 mg
- Form and route
- Tablet · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2015-01-14
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
- Avapro
- PMS-Irbesartan
- Sandoz Irbesartan
- Pro-Irbesartan
- Irbesartan
- Irbesartan
- SPC-Irbesartan
- Riva-Irbesartan
- M-Irbesartan
- Jamp Irbesartan
- AG-Irbesartan
- NB-Irbesartan
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026General benefit Part III-A
Ontario lists this product as a general benefit under the Ontario Drug Benefit program — Part III-A of the Formulary/CDI. For someone eligible for ODB, it is covered without a drug-specific approval.
- What ODB pays per unit
- $0.2281
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 300mg Tab and will substitute one for another at a pharmacy counter in Ontario.
- Avapro 02237925Sanofi-Aventis Canada Inc
- Irbesartan 02372398Sanis Health Inc
- Irbesartan 02385309Sivem Pharmaceuticals ULC
- Jamp Irbesartan 02545241Jamp Pharma Corporation
- M-Irbesartan 02524848Mantra Pharma Inc
- PMS-Irbesartan 02317087Pharmascience Inc
- Sandoz Irbesartan 02328496Sandoz Canada Incorporated
- SPC-Irbesartan 02406837Sun Pharma Canada Inc
Ontario lists 5 further products in this group that are not currently marketed in Canada. They are not shown.
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Cardiovascular system
- ATC code
- C09CA04
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of C09CA04, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026Health Canada has published a recall or safety alert naming this product. Read it on Health Canada’s own site, and speak to a pharmacist before changing anything about how you take this medication.
MINT-Irbesartan/HCTZ Product Recall (2021-05-26)
Matched on the product name at the start of the notice.
This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Mint-Irbesartan → How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.